Total Payments
$64,842
2024 Payments
$44,829
Companies
47
Transactions
538
Medicare Patients
10,767
Medicare Billing
$1.5M
Payment Breakdown by Category
Research$53,070 (81.8%)
Food & Beverage$10,768 (16.6%)
Travel$862.75 (1.3%)
Other$113.53 (0.2%)
Education$27.35 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $53,070 | 2 | 81.8% |
| Food and Beverage | $10,768 | 527 | 16.6% |
| Travel and Lodging | $862.75 | 4 | 1.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $113.53 | 1 | 0.2% |
| Education | $27.35 | 4 | 0.0% |
Payments by Type
Research
$53,070
2 transactions
General
$11,772
536 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $43,784 | 19 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $10,586 | 50 | $0 (2024) |
| Medtronic Vascular, Inc. | $1,586 | 29 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $1,262 | 79 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $893.49 | 42 | $0 (2024) |
| Amgen Inc. | $857.46 | 45 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $619.61 | 39 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $504.85 | 25 | $0 (2022) |
| Gilead Sciences, Inc. | $478.53 | 22 | $0 (2019) |
| PFIZER INC. | $437.05 | 22 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $44,829 | 60 | E.R. Squibb & Sons, L.L.C. ($43,522) |
| 2023 | $10,763 | 65 | Novartis Pharmaceuticals Corporation ($9,744) |
| 2022 | $745.34 | 44 | Janssen Pharmaceuticals, Inc ($123.43) |
| 2021 | $866.54 | 38 | Janssen Pharmaceuticals, Inc ($156.25) |
| 2020 | $1,111 | 60 | Janssen Pharmaceuticals, Inc ($238.62) |
| 2019 | $1,428 | 75 | Actelion Pharmaceuticals US, Inc. ($171.69) |
| 2018 | $3,347 | 118 | Medtronic Vascular, Inc. ($1,471) |
| 2017 | $1,752 | 78 | Novartis Pharmaceuticals Corporation ($437.01) |
All Payment Transactions
538 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $34.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/17/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $26.66 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $21.88 | General |
| Category: Cardiovascular | ||||||
| 11/19/2024 | ATRICURE, INC. | EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) | Food and Beverage | In-kind items and services | $154.80 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/11/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/08/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $26.29 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/31/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $18.77 | General |
| 10/30/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: Cardiology | ||||||
| 10/29/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $28.15 | General |
| Category: Not Applicable | ||||||
| 10/23/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $2.85 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/17/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $43,500.00 | Research |
| Study: Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants | ||||||
| 10/07/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Diabetes | ||||||
| 09/18/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: Cardiology | ||||||
| 09/16/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $32.39 | General |
| Category: Heart Failure and Hypertension | ||||||
| 09/11/2024 | Penumbra, Inc. | Indigo System (Device) | Food and Beverage | Cash or cash equivalent | $32.93 | General |
| Category: Peripheral Intervention | ||||||
| 09/04/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: Diabetes | ||||||
| 09/04/2024 | AGEPHA Pharma FZ LLC | LODOCO (Drug) | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: Cardiovascular Diseases | ||||||
| 09/04/2024 | ATRICURE, INC. | EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/03/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/27/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/08/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $28.15 | General |
| Category: Cardiology | ||||||
| 07/30/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $13.64 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/29/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: Cardiology | ||||||
| 07/18/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants | E.R. Squibb & Sons, L.L.C. | $43,500 | 1 |
| A Phase I, randomized, open-label, single center, crossover study to evaluate the effect of food on the pharmacokinetics of TNO155 in healthy participants | Novartis Pharmaceuticals Corporation | $9,570 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 3,196 | 5,284 | $1.3M | $420,506 |
| 2022 | 22 | 2,807 | 4,768 | $1.1M | $411,024 |
| 2021 | 18 | 2,319 | 3,808 | $912,824 | $349,562 |
| 2020 | 20 | 2,445 | 3,935 | $870,971 | $317,978 |
Total Patients
10,767
Total Services
17,795
Medicare Billing
$1.5M
Procedure Codes
91
All Medicare Procedures & Services
91 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 714 | 1,646 | $355,821 | $149,569 | 42.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 480 | 489 | $194,695 | $71,471 | 36.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 116 | 535 | $80,179 | $33,097 | 41.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 95 | 95 | $86,517 | $31,296 | 36.2% |
| 36475 | Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | Office | 2023 | 11 | 28 | $77,212 | $23,350 | 30.2% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 109 | 436 | $130,800 | $18,393 | 14.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 95 | 95 | $33,910 | $10,939 | 32.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 72 | 77 | $35,836 | $10,466 | 29.2% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 54 | 55 | $27,088 | $10,064 | 37.2% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 42 | 42 | $40,310 | $9,260 | 23.0% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 58 | 62 | $23,281 | $8,262 | 35.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 611 | 699 | $24,546 | $6,994 | 28.5% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 103 | 114 | $61,800 | $6,360 | 10.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 68 | 88 | $18,087 | $5,385 | 29.8% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 89 | 90 | $12,631 | $4,887 | 38.7% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Office | 2023 | 19 | 55 | $12,931 | $4,824 | 37.3% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 31 | 139 | $6,459 | $2,325 | 36.0% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 16 | 16 | $6,208 | $2,228 | 35.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 219 | 303 | $7,575 | $1,933 | 25.5% |
| 99284 | Emergency department visit with moderate level of medical decision making | Facility | 2023 | 17 | 20 | $4,671 | $1,896 | 40.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $5,283 | $1,629 | 30.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 28 | 28 | $4,365 | $1,503 | 34.4% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 22 | 22 | $3,794 | $1,032 | 27.2% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 11 | 16 | $2,028 | $967.78 | 47.7% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 16 | 21 | $1,809 | $706.24 | 39.1% |
About Dr. John Gresham, M.D
Dr. John Gresham, M.D is a Interventional Cardiology healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1619170347.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Gresham, M.D has received a total of $64,842 in payments from pharmaceutical and medical device companies, with $44,829 received in 2024. These payments were reported across 538 transactions from 47 companies. The most common payment nature is "" ($53,070).
As a Medicare-enrolled provider, Gresham has provided services to 10,767 Medicare beneficiaries, totaling 17,795 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 91 distinct procedure/service records.
Ad
Practice Information
- Specialty Interventional Cardiology
- Other Specialties Cardiovascular Disease, Cardiovascular Disease
- Location San Antonio, TX
- Active Since 06/08/2007
- Last Updated 09/14/2022
- Taxonomy Code 207RI0011X
- Entity Type Individual
- NPI Number 1619170347
Products in Payments
- XARELTO (Drug) $1,260
- ENTRESTO (Drug) $832.83
- VenaSeal (Device) $802.93
- ClosureFast (Device) $697.00
- Repatha (Biological) $578.88
- BRILINTA (Drug) $449.09
- ELIQUIS (Drug) $394.65
- MULTAQ (Drug) $361.50
- NEXLETOL (Drug) $353.31
- Impella (Device) $346.10
- OPSUMIT MACITENTAN (Drug) $317.32
- Vascepa (Drug) $294.94
- Corlanor (Drug) $268.58
- PRALUENT (Drug) $258.11
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) $212.23
- UPTRAVI (Drug) $210.75
- Edarbi (Drug) $204.68
- LEQVIO (Drug) $182.89
- VERQUVO (Drug) $182.51
- CHANTIX (Drug) $163.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Interventional Cardiology Doctors in San Antonio
Dr. Anand Prasad, Md, MD
Interventional Cardiology — Payments: $363,638
Interventional Cardiology $363,638
Dr. Nandish Thukral, M.d, M.D
Interventional Cardiology — Payments: $320,616
Interventional Cardiology $320,616
Dr. Ahmed Almomani, Md, MD
Interventional Cardiology — Payments: $100,728
Interventional Cardiology $100,728
Dr. Jorge Alvarez, Md, MD
Interventional Cardiology — Payments: $72,380
Interventional Cardiology $72,380
Devang Patel, Md, MD
Interventional Cardiology — Payments: $27,940
Interventional Cardiology $27,940
Salvatore Barbaro, M.d, M.D
Interventional Cardiology — Payments: $23,527
Interventional Cardiology $23,527